COMPASS Pathways Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

COMPASS Pathways wird ein jährliches Gewinn- und Umsatzwachstum von 9.8% bzw. 90.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -54.8% betragen.

Wichtige Informationen

9.8%

Wachstumsrate der Gewinne

18.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	90.6%
Zukünftige Eigenkapitalrendite	-54.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Feb 08

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Dec 06

Booker again pushes for easier access to psychedelics for terminally ill patients

Oct 19

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

Aug 13

COMPASS Pathways And The Trillion Dollar Opportunity

Aug 11

COMPASS Pathways ADS Q2 2022 Earnings Preview

Aug 03

COMPASS Pathways names new CEO

Jul 19

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

Jun 30

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Apr 28

Checking In On Compass Pathways

Mar 02

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Dec 29

Compass Pathways: Psychedelics For Mental Health

Nov 23

Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy

Sep 17

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

Sep 15

Compass Pathways: Huge Growth Potential, But I'm Cautious

Jun 04

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

May 25

COMPASS Pathways raises $144M capital via equity offering

Apr 30

COMPASS Pathways launches public offering

Apr 27

We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate

Feb 08

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

Jan 01

Compass Pathways: Risky And Overvalued

Dec 18

What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Dec 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CMPS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-154	-141	-134	6
12/31/2025	N/A	-153	-136	-134	7
12/31/2024	N/A	-157	-116	-115	8
9/30/2024	N/A	-144	-105	-105	N/A
6/30/2024	N/A	-139	-100	-100	N/A
3/31/2024	N/A	-129	-91	-90	N/A
12/31/2023	N/A	-118	-97	-97	N/A
9/30/2023	N/A	-117	-115	-115	N/A
6/30/2023	N/A	-102	-117	-117	N/A
3/31/2023	N/A	-95	-111	-110	N/A
12/31/2022	N/A	-92	-106	-105	N/A
9/30/2022	N/A	-86	-83	-83	N/A
6/30/2022	N/A	-84	-78	-77	N/A
3/31/2022	N/A	-80	-77	-77	N/A
12/31/2021	N/A	-72	-68	-68	N/A
9/30/2021	N/A	-65	-62	-62	N/A
6/30/2021	N/A	-66	-62	-62	N/A
3/31/2021	N/A	-64	-51	-51	N/A
12/31/2020	N/A	-60	-42	-41	N/A
9/30/2020	N/A	-49	-31	-31	N/A
6/30/2020	N/A	-38	-22	-22	N/A
3/31/2020	N/A	-25	-19	-19	N/A
12/31/2019	N/A	-20	-18	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CMPS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CMPS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CMPS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CMPS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CMPS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CMPS wird voraussichtlich in 3 Jahren unrentabel sein.

COMPASS Pathways Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.3% to US$38.22

Price target decreased by 8.1% to US$39.50

Price target decreased by 7.4% to US$42.38

Price target decreased to US$55.09

Price target decreased to US$60.22

Price target decreased to US$67.67

Recent updates

New minor risk - Share price stability

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

COMPASS Pathways plc Announces Business Updates

COMPASS Pathways plc to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Shareholder dilution

Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision

Price target decreased by 7.3% to US$38.22

COMPASS Pathways plc Appoints Gino Santini as Chairman Effective September 3, 2024

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Compass Pathways plc Appoints Lori Englebert as Chief Commercial Officer, Effective July 8, 2024

Insider recently sold US$123k worth of stock

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

COMPASS Pathways plc, Annual General Meeting, May 09, 2024

Price target decreased by 8.1% to US$39.50

Chairman & Co-founder notifies of intention to sell stock

New major risk - Shareholder dilution

Co-Founder & Director recently sold US$305k worth of stock

COMPASS Pathways plc to Report Q4, 2023 Results on Feb 29, 2024

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Chairman & Co-founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

COMPASS Pathways plc Announces Management Changes

COMPASS Pathways plc Announces Chief Financial Officer Changes

Price target decreased by 7.4% to US$42.38

COMPASS Pathways plc to Report Q3, 2023 Results on Nov 02, 2023

Compass Pathways plc Announces Executive Changes, Effective November 3 ,2023

Compass Pathways plc Announces the Appointment of Daphne Karydas to Its Board of Directors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

COMPASS Pathways plc announced that it expects to receive $125 million in funding from a group of investors

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New major risk - Financial position

Compass Pathways Announces Resignation of Ekaterina Malievskaia as Chief Innovation Officer, Effective from June 16, 2023

Compass Pathways plc Announces Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of Comp360 Psilocybin Therapy to Be Presented At Asco 2023

COMPASS Pathways plc to Report Q1, 2023 Results on May 11, 2023

COMPASS Pathways plc Announces COMP360 Psilocybin Therapy Shows Potential in Open-Label Study in Type II Bipolar Disorder Presented At ACNP

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Price target decreased to US$55.09

Booker again pushes for easier access to psychedelics for terminally ill patients

Price target decreased to US$60.22

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

COMPASS Pathways And The Trillion Dollar Opportunity

Price target decreased to US$67.67

COMPASS Pathways ADS Q2 2022 Earnings Preview

COMPASS Pathways plc Launches Phase II Clinical Trial of Psilocybin Therapy in Anorexia Nervosa

COMPASS Pathways plc to Report Q2, 2022 Results on Aug 04, 2022

Compass Pathways Appoints Kabir Nath as Chief Executive Officer

COMPASS Pathways names new CEO

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

COMPASS Pathways plc Presents Largest Ever Study of Psilocybin Therapy, At American Psychiatric Association Annual Meeting

Price target decreased to US$70.90

Co-Founder notifies of intention to sell stock

Compass Pathways plc Announces Positive Data Demonstrating the Potential of COMP360 Psilocybin Therapy in Anorexia Nervosa and Severe Treatment-Resistant Depression Has Been Presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from Two Investigator-Initiated Studies

COMPASS Pathways plc to Report Q1, 2022 Results on May 10, 2022

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

COMPASS Pathways plc, Annual General Meeting, Jun 16, 2022

COMPASS Pathways plc Announces Jason Camm Not to Stand for Re-Election as A Director

Checking In On Compass Pathways

Consensus forecasts updated

Price target decreased to US$75.60

COMPASS Pathways plc to Report Q4, 2021 Results on Feb 24, 2022

COMPASS Pathways plc Study of 89 Healthy Participants Published in Journal of Psychopharmacology

General Counsel & Chief Legal Officer notifies of intention to sell stock

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Compass Pathways Announces Positive Outcome of 25Mg Comp360 Psilocybin Therapy as Adjunct to Ssri Antidepressants in Open-Label Treatment-Resistant Depression Study

Compass Pathways Announces Further Positive Results from Phase IIb Trial of Investigational Comp360 Psilocybin Therapy for Treatment-Resistant Depression